TRIM25 and non-small cell lung carcinoma: First, TRIM25 interacts with PTEN and mediates K63 linked polyubiquitination, which prevents the plasma translocation and phosphatase activity of PTEN, which results in the activation of AKT/mTOR signaling and increased resistance of non-small cell lung cancer cells (NSCLC) to cisplatin-induced apoptosis [75].